C

Cellectar Biosciences
D

CLRB

1.58500
USD
0.01
(0.63%)
Market Closed
Volume
6,294
EPS
-2
Div Yield
-
P/E
-1
Market Cap
65,412,681
News

Title: Cellectar Biosciences

Sector: Healthcare
Industry: Biotechnology
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.